Impact of FirstDatabank’s decision to no longer list compounding kits, resulting in new barriers in patient access to needed therapies, highlighted in Boston Globe article. Click here to read the full article.
Product packaging and imagery are for representation purposes only and shall constitute the property of Azurity and all applicable affiliates.
The Information contained herein, including product information, is intended only for residents of the United States.
© 2019-2024 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners.
PP-FKS-US-0095
